Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 487-498, August 2009

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events

  • Bo Ahrén, MD, PhD (Professor)

      Affiliations

    • Corresponding Author InformationTel.: +4646 2220758; Fax: +4646 2220757.

Department of Clinical Sciences, Lund University, Lund, Sweden

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1521-690X(09)00022-0

doi:10.1016/j.beem.2009.03.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 487-498, August 2009

Article Tools

* Image Usage & Resolution